IL-23

      RT @MeralElRamahiMD: ⭐️Ustekinumab+MTX vs. UST+PBO in PsA?

      ➡️Additional MTX has no positive impact on UST effic

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      ⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
      Guselkemab vs. Ustekinumab in PsA: Dr. Richard Conway
      4 years ago
      RT @Janetbirdope: #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #usteki

      Janet Pope Janetbirdope

      4 years ago
      #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
      RT @Janetbirdope: So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different

      Janet Pope Janetbirdope

      4 years ago
      So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
      RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
      ⭐️Addition of MTX did not improve dact

      Robert B Chao, MD doctorRBC

      4 years ago
      Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
      RT @doctorRBC: Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabo

      Robert B Chao, MD doctorRBC

      4 years ago
      Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819 https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
      RT @doctorRBC: 2 year study shows low rates of radiographic progression in PsA pts on guselkumab
      #ACR21 @RheumNow Abs#1

      Robert B Chao, MD doctorRBC

      4 years ago
      2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805 https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
      RT @DrPetryna: Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive

      Olga Petryna DrPetryna

      4 years ago
      Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
      RT @RichardPAConway: No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthr

      Richard Conway RichardPAConway

      4 years ago
      No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
      RT @RichardPAConway: Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in Ps

      Richard Conway RichardPAConway

      4 years ago
      Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
      Infection Risk in Offspring Exposed to Biologics: Dr. Rachel Tate
      4 years ago
      PsA.Hands_.jpg
      The Need for Comparative Treatment Trials in Psoriatic Arthritis
      4 years ago
      Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
      RT @synovialjoints: Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA acr

      Dr. Antoni Chan synovialjoints

      4 years ago
      Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6 @RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
      RT @_Castillo_Pedro: Supporting date for Ixekizumab in PsA with symptoms of axial involvement.
      🔹Improvement in QoL (

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Supporting date for Ixekizumab in PsA with symptoms of axial involvement. 🔹Improvement in QoL (SF-36), ASDAS, BASDAI50 🔹Maintained at 52 weeks 🔹Stricter criteria (younger, ⬆️CRP) showed similar results https://t.co/QSJLQTxLcW #ACR21 Abst#3147 @RheumNow
      RT @RichardPAConway: Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need co

      Richard Conway RichardPAConway

      4 years ago
      Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg

      Catch up on Conference Podcasts

      ×